| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7101866 | GLAXOSMITHKLINE CONS | Anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7541350 | GLAXOSMITHKLINE CONS | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| US6858596 | GLAXOSMITHKLINE CONS | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| US9320862 | GLAXOSMITHKLINE CONS | Fluid dispensing device |
Nov, 2024
(6 months from now) | |
| US8752543 | GLAXOSMITHKLINE CONS | Fluid dispensing device |
Apr, 2026
(1 year, 11 months from now) | |
| US8062264 | GLAXOSMITHKLINE CONS | Fluid dispensing device |
Apr, 2026
(1 year, 11 months from now) | |
| US8347879 | GLAXOSMITHKLINE CONS | Fluid dispensing device |
Jul, 2028
(4 years from now) | |
| US8147461 | GLAXOSMITHKLINE CONS | Fluid dispensing device |
Oct, 2028
(4 years from now) | |
Flonase Sensimist Allergy Relief is owned by Glaxosmithkline Cons.
Flonase Sensimist Allergy Relief contains Fluticasone Furoate.
Flonase Sensimist Allergy Relief has a total of 8 drug patents out of which 3 drug patents have expired.
Expired drug patents of Flonase Sensimist Allergy Relief are:
- US7541350
- US6858596
- US7101866
Flonase Sensimist Allergy Relief was authorised for market use on 27 April, 2007.
Flonase Sensimist Allergy Relief is available in spray, metered;nasal dosage forms.
Flonase Sensimist Allergy Relief can be used as otc use: allergy symptom reliever; temporarily relieves these symptoms due to hay fever or other upper respiratory allergies; nasal congestion, runny nose, sneezing, itchy nose, and (itchy water eyes (ages 12 and up)).
The generics of Flonase Sensimist Allergy Relief are possible to be released after 15 October, 2028.
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 27 April, 2007
Treatment: Otc use: allergy symptom reliever; Temporarily relieves these symptoms due to hay fever or other upper respiratory allergies; Nasal congestion, runny nose, sneezing, itchy nose, and (itchy water eyes ...
Dosage: SPRAY, METERED;NASAL
FLONASE SENSIMIST ALLERGY RELIEF family patents
